Compare TIL & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TIL | ATYR |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | 58 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.8M | 46.1M |
| IPO Year | 2021 | N/A |
| Metric | TIL | ATYR |
|---|---|---|
| Price | $7.55 | $0.46 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 9 |
| Target Price | ★ $125.00 | $3.67 |
| AVG Volume (30 Days) | 21.4K | ★ 2.1M |
| Earning Date | 05-08-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.06 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.67 | $0.40 |
| 52 Week High | $33.83 | $7.29 |
| Indicator | TIL | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 26.91 | 40.77 |
| Support Level | $6.85 | $0.42 |
| Resistance Level | $8.30 | $0.86 |
| Average True Range (ATR) | 0.19 | 0.04 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 4.37 | 16.14 |
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).